A Study of Two Different Formulations of LY3502970 in Healthy Participants
A Phase 1 Multiple-Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of 2 Different Formulations of LY3502970 in Healthy Participants
Sponsor: Eli Lilly and Company
This PHASE1 trial investigates Healthy and is currently completed. Eli Lilly and Company leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1
▶ Show 1 earlier version
-
May 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .